Publications
5599 Results
- Journal / Conference
- Cancer Research Communications Mar 7;4(3):682-690
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID38363156
- PMC
- PMC10919207
- Study Number(s)
- CTSU/C80802
CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C infection in Patients with advanced hepatocellular carcinoma
- Journal / Conference
- JAMA Network Open Jan 2;7(1):e2351062
- Year
- 2024
- Research Committee(s)
- Lymphoma
- PMID
- PMID38241048
- PMC
- PMC10799264
- Study Number(s)
- S1826
Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children
- Journal / Conference
- European Journal of Cancer Apr:201:113914
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID: 38359495
- Study Number(s)
- CTSU/C80405
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer
- Journal / Conference
- Blood Jan 12:blood.2023021959. doi: 10.1182/blood.2023021959. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Leukemia
- PMID
- PMID38215395
- PMC
- PMC1110309
- Study Number(s)
- CTSU/A041202
Long Term Follow-up from A041202, A Phase 3 Study of Bendamustine/Rituximab vs Ibrutinib or Ibrutinib/Rituximab Shows Continued Efficacy and Safety of Ibrutinib in Older Adults with CLL
- Journal / Conference
- Cancer Sep 1;130(17):2918-2927
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID38358334
- PMC
- PMC11309904
- Study Number(s)
- S1609
A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 48) in Patients with Advanced Gallbladder Cancer
- Journal / Conference
- J Clin Oncol 42, 2024 (suppl 3; abstr 726); ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA, poster
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
Diversity of Patients Enrolled in SWOG Gastrointestinal Cancers Therapeutic Trials
- Journal / Conference
- Prostate Cancer and Prostatic Diseases Feb 29. doi: 10.1038/s41391-024-00813-3. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID38424319
- Study Number(s)
- S1216
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): a subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel [Brief Report]
- Journal / Conference
- European Urology Oncology Oct;7(5):1097-1104
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID38523017
- Study Number(s)
- S1216
Three- and seven- month prostate-specific antigen levels as prognostic markers for overall survival in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel or bicalutamide
- Journal / Conference
- Cancer Feb 22. doi: 10.1002/cncr.35264. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Palliative Care
- PMID
- PMID38386696
- PMC
- PMC11162313
- Study Number(s)
- S1820
SWOG S1820: A Pilot Randomized Trial of the Altering Intake, Managing Bowel Symptoms Intervention in Survivors of Rectal Cancer (AIMS-RC)
- Journal / Conference
- ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA), poster; J Clin Oncol 42, 2024 (suppl 3; abstr 182)
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405